Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Grader

Showing results (51-60 of 52) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 52 results.
Seminars in Arthritis and Rheumatism|June 11, 2026
OMERACT- determining a core domain set for Sjögren's disease: International focus group seriesDana D DiRenzo, Lee Ang, Caroline O'Brien, et al.
Lancet (London, England)|August 3, 2024
Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging studyBenjamin A Fisher, Xavier Mariette, Athena Papas, et al.
Pageof 6

Showing results (51-60 of 52) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 52 results.
Seminars in Arthritis and Rheumatism|June 11, 2026
OMERACT- determining a core domain set for Sjögren's disease: International focus group seriesDana D DiRenzo, Lee Ang, Caroline O'Brien, et al.
Lancet (London, England)|August 3, 2024
Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging studyBenjamin A Fisher, Xavier Mariette, Athena Papas, et al.
Pageof 6